Clinical bottom line
Cannabidiol (CBD) is increasingly being explored as a potential treatment for anxiety disorders. While preliminary evidence suggests some promise, more rigorous studies are needed to establish its efficacy and safety. Clinicians should remain cautious and consider current evidence as putative rather than definitive.
What the evidence shows
Recent studies have investigated CBD's anxiolytic effects, with some suggesting potential benefits. A systematic review by Blessing et al. (2015) highlighted that preclinical evidence supports CBD's efficacy in reducing anxiety behaviors relevant to multiple disorders, including post-traumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and social anxiety disorder (SAD) [PMID: 26341731]. A more recent randomized controlled trial (RCT) by Masataka (2019) found that CBD significantly reduced anxiety in teenagers with SAD [PMID: 30825480]. Additionally, a study by Shannon et al. (2019) reported that CBD improved anxiety scores in a clinical population, although the study had a small sample size and lacked a control group [PMID: 30624194].
Caveats and uncertainty
Despite promising findings, the evidence base for CBD in anxiety management remains limited. Many studies suffer from small sample sizes, short durations, and methodological limitations. The variability in CBD dosages and formulations further complicates the interpretation of results. Moreover, the long-term safety profile of CBD, particularly at therapeutic doses, is not well established. As noted by Iffland and Grotenhermen (2017), while CBD is generally well-tolerated, potential interactions with other medications and the risk of side effects require further investigation [PMID: 28861514].
How this may change practice
If future research confirms the efficacy and safety of CBD for anxiety disorders, it could offer a novel therapeutic option, particularly for patients who do not respond to traditional treatments. However, until more conclusive evidence is available, clinicians should exercise caution and consider CBD as an adjunct rather than a primary treatment. It is essential to discuss potential benefits and risks with patients, ensuring informed decision-making.